PLoS ONEplosplosonePLOS ONE1932-6203Public Library of ScienceSan Francisco, CA USA10.1371/journal.pone.0310705PONE-D-24-03382Research ArticlePhysical sciencesChemistryChemical compoundsOrganic compoundsCarbohydratesDisaccharidesSucrosePhysical sciencesChemistryOrganic chemistryOrganic compoundsCarbohydratesDisaccharidesSucroseBiology and life sciencesPhysiologyPhysiological processesIngestionMedicine and health sciencesDiagnostic medicineBiology and life sciencesDevelopmental biologyMorphogenesisSexual differentiationMedicine and health sciencesMedical conditionsCongenital disordersPhysical sciencesChemistryChemical compoundsOrganic compoundsCarbohydratesPhysical sciencesChemistryOrganic chemistryOrganic compoundsCarbohydratesMedicine and health sciencesHealth careMedical servicesTelemedicineBiology and life sciencesAnatomyDigestive systemGastrointestinal tractStomachMedicine and health sciencesAnatomyDigestive systemGastrointestinal tractStomachThe sucrose challenge symptoms test optimized for diagnosis of congenital sucrase isomaltase deficiencyThe sucrose challenge symptoms test optimized for diagnosis of congenital sucrase isomaltase deficiencyStreetKasidyInvestigationMethodologyProject administrationWriting – original draftWriting – review & editing1TaoWengConceptualizationInvestigationMethodologyProject administrationSupervisionWriting – review & editing1CashBrooksWriting – review & editing2https://orcid.org/0000-0003-4208-8955LeungJohnWriting – review & editing3HayesChristopherWriting – review & editing4CooperDerickConceptualizationData curationFormal analysisFunding acquisitionMethodologyResourcesSupervisionVisualizationWriting – review & editing1https://orcid.org/0009-0005-8114-4827PetersonWardConceptualizationFormal analysisMethodologyVisualizationWriting – original draftWriting – review & editing1*QOL Medical LLC, Vero Beach, Florida, United States of AmericaUniversity of Texas Health Science Center, Houston, Texas, United States of AmericaBoston Specialists, Boston, Massachusetts, United States of AmericaChildren’s National Hospital, Washington, DC, United States of AmericaDudejaPradeepEditorUniversity of Illinois at Chicago, UNITED STATES OF AMERICA
The authors have declared that no competing interests exist.
* E-mail: wpeterson@qolmed.com18920242024199e0310705292202430820242024Street et alThis is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Background
Congenital sucrase isomaltase deficiency (CSID), an inherited carbohydrate malabsorption disorder, is difficult to diagnose because of overlapping symptoms with other gastrointestinal (GI) diseases. An at-home study was conducted in CSID and healthy adults to evaluate the diagnostic utility of self-reported GI symptoms following administration of a sucrose challenge.
Methods
This study investigated the optimum symptom scoring with a sucrose challenge symptoms test (SCST) for diagnosing CSID in 45 confirmed patients and 118 healthy controls. Subjects self-reported the severity of GI symptoms using a 10-point Likert scale after ingesting 50 grams of sucrose on an empty stomach. The receiver operator characteristics curve (ROC) was used to identify the diagnostic variable with the highest Youden Index, a measure of diagnostic performance.
Results
All six symptoms were significantly worse in the CSID group within 2 hours after the sucrose challenge. The diagnostic variable with the highest Youden Index was worsening in global symptoms scores at 1- and 2-hours (11.7 [CSID] vs 3.2 [Controls]; P<0.001.) Optimized by gender, the sensitivity and specificity for this diagnostic variable were 87% and 81%, respectively.
Conclusions
The SCST is a simple, non-invasive at-home test that can aid in a CSID diagnosis.
The author(s) received no specific funding for this work.Data AvailabilityAll relevant data are within the manuscript and its Supporting Information files. Supporting information file is available from the figshare database (DOI: 10.6084/m9.figshare.25049783).Introduction
Sucrase-isomaltase (SI) breaks down sucrose and other disaccharides into monosaccharides that the body can absorb. Congenital sucrase-isomaltase deficiency (CSID) is a genetic disorder characterized by insufficient SI activity, resulting in post-prandial gastrointestinal bloating, pain, diarrhea, gas, borborygmi, and nausea [1]. Diagnosing CSID is challenging. Presenting symptoms overlap with irritable bowel syndrome, dyspepsia, and other carbohydrate intolerances and GI disorders [2, 3].
The historical gold standard for diagnosing CSID has been the disaccharidase assay, which measures activity in biopsies from an esophagogastroduodenoscopy [4, 5]. However, this assay is invasive, expensive, and not broadly accessible. In addition, it is subject to biopsy site variability, sampling and specimen handling errors and misinterpretation [6]. Non-invasive alternatives such as breath and genetic tests are fraught with other issues [3, 7, 8]. The sucrose challenge symptoms test (SCST) is based on the hypothesis that elicited GI symptoms following ingestion of a large dose of sucrose on an empty stomach can be used to diagnose CSID.
The present study was conducted to determine symptom scores, diagnostic variables, and cutoffs that can optimally distinguish CSID from healthy controls.
MethodsParticipants and study design
This at-home study evaluated changes in self-reported symptoms severities following a sucrose challenge in confirmed CSID (experimental) and healthy (control) groups. The control group comprised individuals with no significant health problems or chronic GI symptoms. The experimental group was diagnosed with CSID (ICD-10 code E74.31) and treated with Sucraid® (sacrosidase) Oral Solution 8500 IU/mL for at least one year at the time of informed consent. Prospective participants with non-CSID-related symptoms (e.g., small intestinal bacterial overgrowth, inflammatory bowel disease, celiac disease, etc.), recent medical procedures, and antibiotic use were excluded. The study was conducted by a single site with telemedicine capabilities and software to collect real-time data via mobile app. Participants were instructed to fast overnight before ingesting 50g sucrose dissolved in water. GI symptom severity was self-reported on a 10-point scale from 0 (no symptoms) to 9 (worst symptom severity) at baseline and every 30 minutes for 4 hours. The dose of 50g of sucrose was selected based on prior studies and clinical guidelines for carbohydrate malabsorption tests [2].
The study aimed to establish optimal cutoffs and reference ranges for symptom scores distinguishing CSID cases from controls. Symptom average and peak severity, total count, change-from-baseline, and time points were analyzed by group and gender. Receiver operator characteristics (ROC) curves assessed diagnostic test predictability using area-under-the-curve (AUC) and Youden Index to determine optimal sensitivity and specificity [9, 10]. This approach focused on effect estimation rather than hypothesis testing. A planned sample size of 50 CSID cases and 120 controls achieved 80% power to detect ≥1.5 differences in symptom severity means using a two-sided t-test with SD = 3.0.
Ethics statement
This study was approved on July 22, 2021 by Advarra Institutional Review Board (approval number Pro00055707) with an approval expiration date of July 22, 2022. Recruitment occurred between August 30, 2021 and January 27, 2022. The study site scheduled and conducted a telemedicine appointment with each prospective participant to discuss the study. After consideration, willing participants provided electronic consent using a 21 CFR Part 11-compliant application by executing a handwritten signature using a computer mouse, touch screen, or stylus. The study site provided a countersignature in the same manner in real time prior to any study-related assessments. The informed consent process was documented by the study team and maintained as part of the participant’s source documentation in the data platform. Minors were not enrolled into this study.
Results
Characteristics of CSID (n = 45) and control (n = 118) study participants are summarized in Table 1. Prior to sucrose ingestion, CSID cases were more symptomatic than controls, with significantly higher mean symptom severity scores for abdominal bloating (1.3 vs. 0.4, p<0.001) and flatulence/abdominal gas (1.1 vs. 0.5, p = 0.013), and a higher mean total number of symptoms (1.7 vs. 1.0, p = 0.017). Following sucrose ingestion, CSID patients reported significantly more symptoms (mean 4.5 vs. 2.3, p<0.001), a higher mean peak symptom severity overall (4.7 vs. 2.4, p<0.001), and a higher mean peak symptom severity for each of the individual symptoms. The symptom with the highest peak severity score in CSID cases was abdominal bloating (3.4 vs. 1.1, p<0.001). From 2 to 4 hours, the severity of all six symptoms and the total count of symptoms experienced were significantly greater in the CSID group (Fig 1).
10.1371/journal.pone.0310705.g001
(A) Averaged self-reported change-from-baseline (CFB) severity scores for six GI symptoms by CSID group (black circles; N = 45) and control group (open circles; N = 118) at 0.5 to 4 hr following sucrose ingestion in 0.5-hr increments. (B) The total number of elicited symptoms in CSID and control groups. A symptom is defined as an “elicited symptom” if the self-reported symptom severity score is increased by at least 1 unit relative to baseline. Asterisks show p-values based on statistical comparisons between CSID and controls at each time point: *(p<0.05), **(p<0.01), ***(p<0.001), **** (p<0.0001).
10.1371/journal.pone.0310705.t001
Characteristics of study participant by gender, race, age, weight, and height.
Gender (%)
Race (%)
Age year (SD)
Weight lbs (SD)
Height in (SD)
Total
White
Asian
Black
Other
Avg
Min
Max
Avg
Min
Max
Avg
Min
Max
CSID
Female
38 (84)
35 (92)
1 (3)
0
2 (5)
47 (14)
20
80
158 (41)
107
293
65 (3)
60
70
Male
7 (16)
7 (100)
0
0
0
42 (17)
19
63
159 (32)
123
205
70 (3)
66
74
Overall
45 (100)
42 (93)
1 (2)
0
2 (4)
46 (15)
19
80
158 (40)
107
293
66 (4)
60
74
Control
Female
89 (75)
67 (75)
6 (7)
12 (13)
4 (4)
46 (14)
20
74
173 (51)
90
375
65 (3)
58
76
Male
30 (25)
24 (80)
2 (7)
3 (10)
1 (3)
46 (15)
23
70
196 (39)
125
265
69 (3)
61
74
Overall
119 (100)
91 (76)
8 (7)
15 (13)
5 (4)
46 (14)
20
74
179 (49)
90
375
66 (4)
58
76
P-value
Overall
0.267
0.065
0.951
0.006
0.73
The diagnostic variable with the highest overall specificity and sensitivity for differentiating CSID from controls was a worsening in global symptoms score (GSS) at 1 and 2 hours (11.7 ± 10.06 vs 3.2 ± 7.09; p< 0.001). Table 2 shows gender specific cut-offs of five for females and three for males, which resulted in Youden Index, sensitivity, and specificity values of 0.64, 84%, and 80% (females) and 0.83, 100% and 83% (males). When separately optimized by gender and used to identify positive/negative cases, the resulting sensitivity and specificity were 87% and 81%, respectively, for the pooled population.
10.1371/journal.pone.0310705.t002
AUC
Youden Index
Sensitivity
Specificity
Cutoff
CSID Mean (SD)
Control Mean (SD)
p-value
Female
0.83
0.64
0.84
0.80
5
12.2 (10.78)
3.8 (7.88)
<0.001
Male
0.93
0.83
1.00
0.83
3
9.3 (4.19)
1.5 (3.55)
<0.001
Combined
--
0.67
0.87
0.81
5/3
11.7 (10.06)
3.2 (7.09)
<0.001
Summarized results from ROC analysis of global worsening in symptom severity scores at 1- and 2-hr by gender and group.
Discussion
This study used self-reported severity scores to determine whether symptomatic responses following a sucrose load can be used to optimize a scoring method for diagnosing CSID. CSID volunteers consistently reported higher mean severity scores for all six symptoms (abdominal bloating, borborygmi, diarrhea, flatulence, nausea and abdominal pain) at all eight time points (0.5, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hr following sucrose ingestion), and this difference is statistically significant from 2 to 4 hours. The diagnostic variable that best differentiates CSID cases from controls is the gender-specific worsening in GSS at 1 and 2 hr combined.
CSID can present with symptoms similar to those of IBS. Previous studies have shown that sucrase-isomaltase deficiency can be found in a significant proportion of IBS patients [11, 12]. The SCT could potentially be utilized to differentiate CSID from IBS and other conditions with overlapping symptoms. Future studies should focus on comparing the efficacy of SCST in distinguishing these conditions.
The current study does have some limitations. While the sample size approximated a priori power estimations, it fell slightly below the recruitment goals established at the outset of the trial. CSID females outnumbered CSID males by 5:1. The higher number of female subjects in both groups reflects the demographics of the accessible patient population for this study. Future research should aim for a more balanced gender representation. The diagnosis of CSID in the experimental group was not standardized. Furthermore, the selection of confirmed CSID patients as the experimental case group may result in a “nocebo” effect, in which patients’ expectations of symptoms worsening could lead to a perceived increase in symptoms unrelated to the actual ingestion of sucrose. Future studies should consider incorporating a non-sucrose sugar control to mitigate this bias. Finally, treatment with sacrosidase prior to a second SCT would potentially have increased diagnostic certainty regarding sucrose as a causal factor for the generation of GI symptoms among those patients with a positive sucrose challenge test.
This study nevertheless provides evidence to support an optimized GSS after a sucrose challenge as a non-invasive diagnostic tool for identifying adults with CSID. Sensitivities and specificities exceeding 80% were achieved based on self-reported scoring of six GI symptoms on a 10-point scale at only three time points (baseline, 1 and 2 hr). The SCST is non-invasive and does not require an in-clinic visit. Unlike the hydrogen-methane breath test, it is not dependent on measuring byproducts of commensal bacterial fermentation [2, 7]. No unintended or harmful adverse events were observed with the SCST. In conclusion, the SCST could serve as a useful, safe and practical diagnostic tool to help identify CSID patients.
Supporting information
Sucrose challenge symptoms data.
(XLSX)
ReferencesTreemWR. Clinical aspects and treatment of congenital sucrase-isomaltase deficiency. J Pediatr Gastroenterol Nutr. 2012Nov;55 Suppl 2:S7–13. doi: 10.1097/01.mpg.0000421401.57633.9023103658.RezaieA, BuresiM, LemboA, LinH, McCallumR, RaoS, et al. Hydrogen and methane-based breath testing in gastrointestinal disorders: The North American Consensus. Am J Gastroenterol. 2017May;112(5):775–84. doi: 10.1038/ajg.2017.4628323273; PubMed Central PMCID: PMC5418558.Amieva-BalmoriM, Coss-AdameE, RaoNS, Dávalos-PantojaBM, RaoSSC. Diagnostic utility of carbohydrate breath tests for sibo, fructose, and lactose intolerance. Dig Dis Sci. 2020May;65(5):1405–13. doi: 10.1007/s10620-019-05889-931617133.BurkeM.Carbohydrate intolerance and disaccharidase measurement–a mini-review. Clin Biochem Rev. 2019Nov;40(4):167–74. doi: 10.33176/AACB-19-0002531857738; PubMed Central PMCID: PMC6892707.DailedaT, BaekP, SutterME, ThakkarK. Disaccharidase activity in children undergoing esophagogastroduodenoscopy: A systematic review.World J Gastrointest Pharmacol Ther. 2016May6;7(2):283–93. doi: 10.4292/wjgpt.v7.i2.28327158545; PubMed Central PMCID: PMC4848252.ReedRC, PachecoMC. Clinical and histopathologic predictors of disaccharidase deficiency in duodenal biopsy specimens. Am J Clin Pathol. 2019Nov4;152(6):742–6. doi: 10.1093/ajcp/aqz09131332425.GhoshalUC. How to interpret hydrogen breath tests.J Neurogastroenterol Motil.2011Jul;17(3):312–7. doi: 10.5056/jnm.2011.17.3.31221860825; PubMed Central PMCID: PMC3155069.SaadRJ, CheyWD. Breath tests for gastrointestinal disease: the real deal or just a lot of hot air?Gastroenterology2007Dec;133(6):1763–6. doi: 10.1053/j.gastro.2007.10.05918054546.YoudenWJ. Index for rating diagnostic tests. Cancer1950Jan;3(1):32–5. doi: 10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-315405679.HanleyJA, McneilBJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology1982Apr;143(1):29–36. doi: 10.1148/radiology.143.1.70637477063747Garcia-EtxebarriaK, ZhengT, BonfiglioF, BujandaL, DlugoszA, LindbergG, et al. Increased prevalence of rare sucrase-isomaltase pathogenic variants in irritable bowel syndrome patients. Clin Gastroenterol Hepatol2018Oct;16(10):1673–6doi: 10.1016/j.cgh.2018.01.04729408290; PubMed Central PMCID: PMC6103908.KimSB, CalmetFH, GarridoJ, Garcia-BuitragoMT, MoshireeB. Sucrase-isomaltase deficiency as a potential masquerader in irritable bowel syndrome. Dig Dis Sci2020Feb;65(2):534–40. doi: 10.1007/s10620-019-05780-731493040.